|
|
|
| Efficacy and adverse reactions of antigen-loaded dendritic cell vaccine in combination with various T cells on nonsmall-cell lung cancer |
| WANG Zuozhi1, XIE Shangyun2, LIU Qingyun1, WEI Changhong1, BIAN Xiaoshan1 |
| 1. Department of Oncology, 2. Biotherapy Center, Shandong Provincial Corps Hospital of Chinese People’s Armed Police Forces, Jinan 250014 ,China |
|
|
|
|
Abstract Objective To evaluate the clinical efficacy and adverse reaction of antigen-loaded dendritic cells(DC)vaccine in combination with cytokine-induced killer cells(CIK), gamma delta receptors of T cells(γδT)and natural killer cells(NK)on 24 patients with lung cancer. Methods Mononuclear cells isolated by blood apheresis were induced into productions of DC, γδT, CIK and NK cells by corresponding cytokines in vitro. All patients received a course of treatment including intravenous infusion and intradermal injection of DC vaccine for four times, intravenous infusion of γδT, CIK each 3 times and intravenous infusion of NK cells twice, a total of 12 times. Clinical and immunologic responses were evaluated by imaging examination,T lymphocytes subset changes, respectively. Results 22 patients were enrolled in this study. During 5-24 months follow-up(median,10 months),partial remission(PR)in 9 cases,stability of disease(SD) in 11 cases,and progression of disease(PD) in 2 cases was identified with measurable diseases progress. After 2 months treatment,the levels of CD3+、CD4+、CD56+ increased very significantly(P<0.001). No severe adverse events were observed except 2 patients with mild fever and 1 patient had muscular soreness. Conclusions Antigen-pulsed DCs in combination with various T cells shows short-term efficacy on lung cancer through inducing specific antitumor immunity.
|
|
Received: 15 October 2014
|
|
|
|
|
|
| [1] |
Schmidt-Wolf G D,Negrin R S,Schmidt-Wolf I G. Activated T cells and cytokine-induced CD3+CD56+ killer cells[J].Ann Hematol,1997,74(2):51- 56.
|
| [5] |
Morse M A,Coleman R E,Akabani G,et al. Migration of human dendritic cells after injection in patients with metastaticmalignancies[J]. Cancer Res,1999,59(1):56-58.
|
| [6] |
Adwani S H,Kutty P M,Copal R, et al. Immunity in oesophageal carcinomal[J].J Surg Oncol,1983,24(4):268.
|
| [2] |
Jung H K, Yoom L, Yong-Soo B, et al. Phase Ⅰ/Ⅱ study of immunotherapy using autologous tumor Lysate-pulsed dendritic cells in patients with meatastatic renal cell carcinoma[J].Clin Immunol, 2007, 12(5):257-267.
|
| [7] |
Olsen G N,Cangemi J D.Bronchoalveolar layage and the immunologe of primary lung cancer[J].Chest,1985,87(5):677-683.
|
| [8] |
Mitropoulos D,Alamanis C,Deliveliotts C, et al.T-lymphocyte subsets in the periphcral blood of patients with renal cell carcinoma[J].Arta Urol Belg,1995,63(3) :21-25.
|
| [3] |
Hwan Mook Kim, Jaeseung Lim, Song-Kyu Park, et al. Antitumor activity of cytokine-induced killer cell against human lung cancer[J]. Int Immunopharmacol,2007, 24(5):1802-1807.
|
| [4] |
Holtl L,Zelle-Rieser C,Gander H,et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsedautologous dendritic cells[J]. Clin Cancer Res,2002,8(11):3369- 3376.
|
| [5] |
Morse M A,Coleman R E,Akabani G,et al. Migration of human dendritic cells after injection in patients with metastaticmalignancies[J]. Cancer Res,1999,59(1):56-58.
|
| [6] |
Adwani S H,Kutty P M,Copal R, et al. Immunity in oesophageal carcinomal[J].J Surg Oncol,1983,24(4):268.
|
| [7] |
Olsen G N,Cangemi J D.Bronchoalveolar layage and the immunologe of primary lung cancer[J].Chest,1985,87(5):677-683.
|
| [8] |
Mitropoulos D,Alamanis C,Deliveliotts C, et al.T-lymphocyte subsets in the periphcral blood of patients with renal cell carcinoma[J].Arta Urol Belg,1995,63(3) :21-25.
|
|
|
|
2015, Vol. 26 
